Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Roche Holding AG
  6. News
  7. Summary
    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Roche : Regeneron COVID-19 Antibody Cocktail Reduces Death Risk in Late-Stage Trial

06/16/2021 | 03:52am EDT


ę MT Newswires 2021
All news about ROCHE HOLDING AG
10:38aPTC THERAPEUTICS : Significant Improvements in Survival and Developmental Milest..
AQ
05:35aROCHE : Morningstar Lowers Price Target on Roche, Maintains Buy Recommendation
MT
03:55aROCHE : Evrysdi Meets Primary Endpoint In Infants With Spinal Muscular Atrophy
MT
03:53aROCHE : Eye Drug Accepted For Priority Review In US
MT
01:03aPRESS RELEASE : FDA accepts application for -3-
DJ
01:03aPRESS RELEASE : FDA accepts application for -2-
DJ
01:03aPRESS RELEASE : FDA accepts application for Roche's faricimab for the treatment ..
DJ
01:03aROCHE : FDA accepts application for Roche's faricimab for the treatment of neova..
AQ
01:03aFDA Accepts Application for Roche’s Faricimab for the Treatment of Neovascula..
CI
01:01aPRESS RELEASE : Data for Roche's Evrysdi(R) -2-
DJ
More news
Financials
Sales 2021 60 771 M 67 031 M 67 031 M
Net income 2021 14 459 M 15 948 M 15 948 M
Net cash 2021 4 697 M 5 180 M 5 180 M
P/E ratio 2021 20,4x
Yield 2021 2,70%
Capitalization 303 B 335 B 335 B
EV / Sales 2021 4,92x
EV / Sales 2022 4,75x
Nbr of Employees 101 465
Free-Float 83,4%
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | ROG | CH0012032048 | MarketScreener
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 347,60 CHF
Average target price 375,75 CHF
Spread / Average Target 8,10%
EPS Revisions
Managers and Directors
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Technology Officer
Christoph Franz Chairman
Urs Jaisli Chief Compliance Officer
AndrÚ S. Hoffmann Vice Chairman
Sector and Competitors
1st jan.Capi. (M$)
ROCHE HOLDING AG12.49%332 374
JOHNSON & JOHNSON9.40%453 418
PFIZER, INC.18.04%243 220
ELI LILLY AND COMPANY46.00%224 084
NOVARTIS AG0.39%223 750
ABBVIE INC.10.64%209 386